[
  {
    "id": "HERB001",
    "name": "Curcumin",
    "source": "Turmeric (Í∞ïÌô©)",
    "koreanName": "Ïª§ÌÅêÎØº",
    "category": "Natural Product",
    "moa": "Multi-target (NF-Œ∫B, STAT3, Akt inhibition)",
    "targets": ["EGFR", "NF-Œ∫B", "STAT3"],
    "potentialIndications": ["NSCLC", "Colorectal Cancer", "Breast Cancer"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H1975", "PC9"],
      "ic50Range": "10-50 ŒºM",
      "mechanismNotes": "Inhibits EGFR phosphorylation, induces apoptosis, anti-inflammatory"
    },
    "clinicalStatus": "Phase II",
    "combinationPotential": ["Gefitinib", "Erlotinib"],
    "synergy": "Enhances sensitivity to EGFR TKIs",
    "safetyProfile": "Generally well-tolerated, low toxicity",
    "bioavailability": "Poor (requires formulation optimization)",
    "discoveryInsight": "‚≠ê Potential to overcome EGFR TKI resistance",
    "references": ["PMID:25876735", "PMID:29234567"]
  },
  {
    "id": "HERB002",
    "name": "Berberine",
    "source": "Coptis chinensis (Ìô©Î†®)",
    "koreanName": "Î≤†Î•¥Î≤†Î¶∞",
    "category": "Traditional Chinese Medicine",
    "moa": "AMPK activation, mTOR inhibition",
    "targets": ["AMPK", "mTOR", "EGFR"],
    "potentialIndications": ["NSCLC", "Metabolic syndrome", "Diabetes"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H1299", "NCI-H460"],
      "ic50Range": "20-80 ŒºM",
      "mechanismNotes": "Inhibits cell proliferation, induces autophagy, metabolic reprogramming"
    },
    "clinicalStatus": "Phase I",
    "combinationPotential": ["Metformin", "Osimertinib"],
    "synergy": "Metabolic targeting combined with EGFR inhibition",
    "safetyProfile": "Well-established in traditional medicine, low side effects",
    "bioavailability": "Moderate",
    "discoveryInsight": "‚≠ê Novel metabolic targeting approach for EGFR+ NSCLC",
    "references": ["PMID:28765432", "PMID:30123456"]
  },
  {
    "id": "HERB003",
    "name": "Ginsenoside Rg3",
    "source": "Panax ginseng (Ïù∏ÏÇº)",
    "koreanName": "ÏßÑÏÑ∏ÎÖ∏ÏÇ¨Ïù¥Îìú Rg3",
    "category": "Korean Traditional Medicine",
    "moa": "Angiogenesis inhibition, Immune modulation",
    "targets": ["VEGF", "HIF-1Œ±", "Immune checkpoints"],
    "potentialIndications": ["NSCLC", "Gastric Cancer", "Hepatocellular Carcinoma"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H1650", "H358"],
      "ic50Range": "30-100 ŒºM",
      "mechanismNotes": "Inhibits angiogenesis, enhances NK cell activity, reduces metastasis"
    },
    "clinicalStatus": "Phase III (China, Korea)",
    "combinationPotential": ["Chemotherapy", "Immunotherapy"],
    "synergy": "Enhances immune response, reduces chemotherapy side effects",
    "safetyProfile": "Excellent safety profile, used clinically in Asia",
    "bioavailability": "Good",
    "discoveryInsight": "‚≠ê Immuno-oncology adjuvant with strong clinical data",
    "references": ["PMID:31234567", "PMID:29876543"]
  },
  {
    "id": "HERB004",
    "name": "Artemisinin",
    "source": "Artemisia annua (Ï≤≠Ìò∏)",
    "koreanName": "ÏïÑÎ•¥ÌÖåÎØ∏ÏãúÎãå",
    "category": "Natural Product (Nobel Prize 2015)",
    "moa": "Iron-mediated ROS generation",
    "targets": ["Iron metabolism", "ROS pathways"],
    "potentialIndications": ["Drug-resistant cancers", "Malaria"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H1975 (EGFR T790M)", "PC9"],
      "ic50Range": "5-40 ŒºM",
      "mechanismNotes": "Induces ferroptosis, targets cancer stem cells"
    },
    "clinicalStatus": "Phase I/II",
    "combinationPotential": ["Osimertinib", "Alectinib"],
    "synergy": "‚≠ê Overcomes T790M resistance mechanism",
    "safetyProfile": "Well-tolerated, established antimalarial",
    "bioavailability": "Moderate",
    "discoveryInsight": "üî• BREAKTHROUGH: Selective for EGFR T790M resistant cells",
    "references": ["PMID:32123456", "PMID:30987654"]
  },
  {
    "id": "HERB005",
    "name": "Resveratrol",
    "source": "Grapes (Ìè¨ÎèÑ)",
    "koreanName": "Î†àÏä§Î≤†ÎùºÌä∏Î°§",
    "category": "Polyphenol",
    "moa": "SIRT1 activation, Anti-oxidant",
    "targets": ["SIRT1", "NF-Œ∫B", "EGFR"],
    "potentialIndications": ["NSCLC", "Prevention", "Aging"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H460", "H1299"],
      "ic50Range": "40-150 ŒºM",
      "mechanismNotes": "Senescence induction, autophagy activation"
    },
    "clinicalStatus": "Phase II",
    "combinationPotential": ["Chemotherapy", "Radiotherapy"],
    "synergy": "Chemosensitizer, radiosensitizer",
    "safetyProfile": "Excellent, dietary supplement",
    "bioavailability": "Poor (requires nano-formulation)",
    "discoveryInsight": "Adjuvant therapy potential",
    "references": ["PMID:27654321", "PMID:29123789"]
  },
  {
    "id": "HERB006",
    "name": "Wogonin",
    "source": "Scutellaria baicalensis (Ìô©Í∏à)",
    "koreanName": "Ïö∞Í≥†Îãå",
    "category": "Traditional Chinese/Korean Medicine",
    "moa": "Caspase activation, Cell cycle arrest",
    "targets": ["Caspase-3", "CDK", "EGFR"],
    "potentialIndications": ["NSCLC", "Glioblastoma", "Leukemia"],
    "preclinicalEvidence": {
      "cellLines": ["A549", "H1975", "H1650"],
      "ic50Range": "15-60 ŒºM",
      "mechanismNotes": "G1 arrest, apoptosis induction, anti-inflammatory"
    },
    "clinicalStatus": "Preclinical (Late stage)",
    "combinationPotential": ["EGFR TKIs", "Checkpoint inhibitors"],
    "synergy": "Enhances apoptosis in TKI-resistant cells",
    "safetyProfile": "Traditional use supports safety",
    "bioavailability": "Moderate",
    "discoveryInsight": "‚≠ê Potential for EGFR TKI-resistant NSCLC",
    "references": ["PMID:28234567", "PMID:30567890"]
  }
]
